Literature DB >> 17325277

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

P Hau1, D Koch, T Hundsberger, E Marg, B Bauer, R Rudolph, M Rauch, A Brenner, P Rieckmann, J Schuth, T Jauch, H Koch, U Bogdahn.   

Abstract

We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17325277     DOI： 10.1212/01.wnl.0000255937.27012.ee

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  34 in total

1.  Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.

Authors:  Marta Simó; Roser Velasco; Francesc Graus; Eugenia Verger; Miguel Gil; Estela Pineda; Jaume Blasco; Jordi Bruna
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.

Authors:  Nadia Malkoun; Cyrus Chargari; Fabien Forest; Marie-Jeannette Fotso; Lysian Cartier; Pierre Auberdiac; Julie Thorin; Cécile Pacaut; Michel Peoc'h; Christophe Nuti; Thierry Schmitt; Nicolas Magné
Journal:  J Neurooncol       Date:  2011-07-02       Impact factor: 4.130

3.  Tonsillar pseudotumor: complications of chronically-administered temozolomide.

Authors:  Kathleen Grisdale; Melesa Ritterhouse; Kathy Hunter; Michelle D Williams; Morris D Groves
Journal:  J Neurooncol       Date:  2010-05-04       Impact factor: 4.130

4.  Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.

Authors:  Gloria B Roldán Urgoiti; Amitabh D Singh; Jacob C Easaw
Journal:  J Neurooncol       Date:  2012-03-02       Impact factor: 4.130

Review 5.  Straying from the path in neuro-oncology.

Authors:  J Lee Villano; Thomas Pittman
Journal:  Neuro Oncol       Date:  2014-06-18       Impact factor: 12.300

6.  Treatment of glioblastoma in elderly patients.

Authors:  Florian Stockhammer
Journal:  CNS Oncol       Date:  2014-03

Review 7.  Treating recurrent glioblastoma: an update.

Authors:  Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal:  CNS Oncol       Date:  2015

8.  Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report.

Authors:  Asim Jamal Shaikh; Nehal Masood
Journal:  J Med Case Rep       Date:  2010-08-18

9.  Temozolomide in malignant glioma.

Authors:  Gregor Dresemann
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

10.  RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.

Authors:  Christoph P Beier; Christina Schmid; Thierry Gorlia; Christine Kleinletzenberger; Dagmar Beier; Oliver Grauer; Andreas Steinbrecher; Birgit Hirschmann; Alexander Brawanski; Christopher Dietmaier; Tanja Jauch-Worley; Oliver Kölbl; Torsten Pietsch; Martin Proescholdt; Petra Rümmele; Armin Muigg; Günther Stockhammer; Monika Hegi; Ulrich Bogdahn; Peter Hau
Journal:  BMC Cancer       Date:  2009-09-02       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.